We previously identified the selective androgen receptor (AR) modulator S42, which does not stimulate prostate growth but has a beneficial effect on lipid metabolism. In the prostate cancer (PC) cell line LNCaP, S42 did not induce AR transactivation but antagonized 5a-dihydrotestosterone (DHT)-induced AR activation. Next, we investigated whether S42 suppresses the growth of PC cell lines. Basal growth of LNCaP cells was significantly suppressed by treatment with S42 compared with vehicle, as determined by cell counting and 5-bromo-2 0 -deoxyuridine assays. The suppressive effect of S42 on cell growth was evident in the AR-positive PC cells LNCaP and 22Rv1 and was slightly observed even in the AR-negative PC-3 cells. However, S42 did not induce apoptosis as determined by the terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay. S42 had an even greater suppressive effect on DHT-dependent LNCaP cell proliferation than on basal proliferation (P , 0.05). DHT treatment increased the expression of phosphorylated extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK), a major signaling molecule for PC proliferation, and this was significantly inhibited by S42. DHT also significantly upregulated AR, insulinlike growth factor-1 receptor (IGF-1R), and insulin receptor (IR)-b protein levels, which were similarly reduced by S42 treatment. Importantly, S42 administration to mice attenuated the growth of LNCaP tumors and reduced tumor expression of the prostate-specific antigen, P504S, Ki67, and phosphorylated ERK-MAPK. These data suggest that S42 attenuates LNCaP tumor growth not by inducing apoptosis but by inhibiting the expression of proliferationrelated receptors, including IGF-1R, IR, and AR, and by suppressing ERK-MAPK activation. S42 may thus be a feasible candidate for PC treatment. (Endocrinology 159: 1774(Endocrinology 159: -1792(Endocrinology 159: , 2018 
of S42 on cell growth was evident in the AR-positive PC cells LNCaP and 22Rv1 and was slightly observed even in the AR-negative PC-3 cells. However, S42 did not induce apoptosis as determined by the terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling assay. S42 had an even greater suppressive effect on DHT-dependent LNCaP cell proliferation than on basal proliferation (P , 0.05). DHT treatment increased the expression of phosphorylated extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK), a major signaling molecule for PC proliferation, and this was significantly inhibited by S42. DHT also significantly upregulated AR, insulinlike growth factor-1 receptor (IGF-1R), and insulin receptor (IR)-b protein levels, which were similarly reduced by S42 treatment. Importantly, S42 administration to mice attenuated the growth of LNCaP tumors and reduced tumor expression of the prostate-specific antigen, P504S, Ki67, and phosphorylated ERK-MAPK. These data suggest that S42 attenuates LNCaP tumor growth not by inducing apoptosis but by inhibiting the expression of proliferationrelated receptors, including IGF-1R, IR, and AR, and by suppressing ERK-MAPK activation. S42 may thus be a feasible candidate for PC treatment. (Endocrinology 159: 1774-1792, 2018) P rostate cancer (PC) is the most common malignancy in men worldwide (1, 2) . The fact that .70% of PCs rely on androgen stimulation for growth provided the rationale for androgen ablation therapy, which-although initially effective-invariably results in treatment resistance (3) .
Testosterone deficiency is associated with an increased risk for cardiovascular disease, metabolic syndrome, and sarcopenia, among other complications (4, 5) . We previously reported that male androgen receptor (AR)-knockout mice showed visceral fat obesity as a result of decreased energy expenditure (6) . Consequently, testosterone-replacement therapy was recommended for low-testosterone disorders such as late-onset hypogonadism (4) , but it has the potential to accelerate the progression of latent PC. To mitigate this risk, a class of novel compounds termed selective androgen receptor modulators (SARMs) were developed; these compounds have no major androgenlike effects in the prostate, but they act as agonists in selected androgen-responsive tissues (7, 8) . To develop an SARM with beneficial activity in energy homeostasis, we previously screened 119 steroid analogues for the ability to induce uncoupling protein-1 (UCP1) messenger RNA (mRNA) without increasing prostate-specific antigen (PSA) promoter activity in the human PC cell line LNCaP (9) . From this screen, we identified an SARM, S42, that is a structural analogue of testosterone (9) . In LNCaP cells, S42 does not induce AR transactivation but antagonizes 5a-dihydrotestosterone (DHT)-induced AR activation (9) . Consistent with the in vitro results, administration of S42 to orchiectomized Sprague-Dawley rats for 3 weeks was as effective as DHT in increasing the weight of the levator ani muscle, but it did not elevate prostate weight at any dose, in contrast to the effect of DHT. S42 also showed beneficial effects on lipid metabolism (9) . These results suggest that S42 may inhibit PC cell proliferation while sparing the prostate from potentially harmful effects.
In the current study, we investigated the effect of S42 on the growth of PC cell lines and found that it suppressed cell growth in vitro and in vivo. We showed that S42 inhibited DHT-induced activation of several PC cell-signaling components, including the extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) pathway.
Materials and Methods
Chemicals S42 (Potent, 5789874, Japan) was synthesized by Aska Pharmaceutical Co., Ltd. (Tokyo, Japan). DHT was purchased from Sigma Chemical Co. (St. Louis, MO). For in vitro studies, S42 and DHT were dissolved in dimethyl sulfoxide (DMSO) (Nacalai Tesque, Kyoto, Japan) and ethanol (EtOH), respectively. Cycloheximide (CHX; catalog no. C7698), a protein synthesis inhibitor, was purchased from Sigma Chemical Co., and InSolution MG-132 (catalog no. 474791), a cell-permeable proteasome inhibitor, was purchased from Millipore (Billerica, MA). For animal studies, S42 was dissolved in olive oil (Nacalai Tesque) containing 5% [volume-to-volume ratio (v/v)] DMSO.
Cell culture and cell proliferation assays
The human androgen-sensitive PC cell lines LNCaP and 22Rv1 and the human castration-resistant (androgenindependent) PC cell lines PC-3 and DU145 were purchased from American Type Culture Collection (Manassas, VA). LNCaP, 22Rv1, and DU145 cells were maintained in RPMI 1640 medium (ATCC 30-2001, RPMI-1640 medium modified to contain 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500 mg/L glucose, and 1500 mg/L sodium bicarbonate), and PC-3 cells were cultured in Ham F-12 (11765; Gibco, Invitrogen, Carlsbad, CA) medium. All media were supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cell proliferation assays were performed as described previously (10, 11) , with minor modifications. Briefly, LNCaP, 22Rv1, PC-3, and DU145 cells were seeded at 3 3 10 4 cells per well in 12-well tissue culture plates and maintained in medium containing 10% dextran-coated charcoal-stripped FBS (DCCS-FBS) in the presence of 10 mM of S42 or DMSO vehicle and/or 10 nM of DHT or EtOH vehicle. The cell number was counted daily for up to 4 days using a hemocytometer. For all experiments, cells were used at passages 4 to 8. Experiments were performed in triplicate using five different cell preparations.
Reverse transcription and quantitative real-time polymerase chain reaction Total RNA was isolated from PC cell lines and tumor xenografts using RNeasy Mini Kits (Qiagen, Venlo, The Netherlands) and reverse-transcribed to complementary DNA. Polymerase chain reactions (PCRs) were performed using a LightCycler 2.0 system (Roche, Basel, Switzerland) and SYBR Premix Ex Taq II (Takara, Otsu, Japan). Each sample was analyzed in triplicate, and mRNA levels were normalized against TATA-binding protein (TBP) mRNA levels. The primer sequences were as follows: human PSA,
5-Bromo-2 0 -deoxyuridine assays 5-Bromo-2 0 -deoxyuridine (BrdU) assays were performed essentially as previously described (9, 10) using Cell Proliferation enzyme-linked immunosorbent assay kits (1647229; Roche Applied Science, Mannheim, Germany). Briefly, PC cells were plated at 5 3 10 3 cells per well in 96-well culture plates in complete media and grown to 60% to 70% confluence. Cells were then treated with 10 mM of S42 or DMSO plus 10 nM of DHT or EtOH in medium containing 10% DCCS-FBS for 24 to 48 hours, and BrdU solution (final concentration, 10 mM) was added for the final 2 hours of incubation. The assay was then performed according to the manufacturer's protocol. The mean BrdU incorporation was calculated, and the data were expressed as the incorporation in treated cells compared with that in control vehicle-treated cells.
Apoptosis assays
The cell apoptosis assay was performed essentially as previously described (10, 11) . In brief, 1.2 3 10 5 PC cells were plated on glass coverslips in Laboratory-Tek Chamber Slides (177380, Nunc; Thermo Scientific, Waltham, MA) and fixed in 4% paraformaldehyde for 25 minutes. Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) staining was performed using the DeadEnd Fluorometric TUNEL System (Promega, Madison, WI) according to the manufacturer's protocol. During the final 24 to 48 hours of incubation, cells were treated with 10 mM of S42 or DMSO plus 10 nM of DHT or EtOH. Cells treated with 1 unit/100 mL RQ1 RNase-Free DNase (M6101; Promega) for 48 hours were used as the positive control.
Western blot analysis
Western blot analysis was performed essentially as previously described (9, 10) . PC cells were treated with 10 mM of S42 or DMSO plus 10 nM of DHT or EtOH in medium containing 10% DCCS-FBS for 24 hours. LNCaP cells were also pretreated with CHX (50 mg/mL) or MG-132 (10 mmol/L) for 30 minutes followed by incubation with the indicated combinations of DMSO, EtOH, 10 mM of S42, and 10 nM of DHT for different times. The cells were then lysed with RIPA buffer (50 mmol/L Tris-HCl, pH 7.6, 150 mmol/l NaCl, 1% NP40, 0.5% sodium deoxycholate, protease inhibitor cocktail, 0.1% sodium dodecyl sulfate). Samples of 10 mg of total protein were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. The blots were then incubated with the following expression. Additional information on antibodies used in this study is listed in Table 1 .
Animal study
All procedures for the animal experiments were approved by the institutional Animal Care Subcommittee at Fukuoka University. Male CAnN.Cg-Foxn1 nu /CrlCrlj (BALB/c nude) mice (5 weeks of age) were purchased from Charles River Laboratories Japan, Inc., and housed in specific pathogen-free barrier facilities. At 6 weeks of age, the mice were injected subcutaneously with 2 3 10 5 cytomegalovirus-luciferase (CAG-Luc) LNCaP cells (stably transfected with a CAG firefly luciferase reporter plasmid (catalog no. LVP567; GenTarget Inc., San Diego, CA) mixed with 100 mL of Matrigel (Becton Dickinson, Bedford, MA). Two weeks after cell injections, the mice (n = 6 or 7) were subcutaneously injected with S42 (0.1 or 1 mg/kg of body weight (BW)] or vehicle [95% (v/v) olive oil and 5% (v/v) DMSO] twice a week for 4 weeks. At 12 weeks of age, the mice were anesthetized for blood sampling and then euthanized. Serum PSA levels were measured by SRL Inc. (Tokyo, Japan) using an enzyme immunoassay.
Tumor growth was evaluated weekly using an IVIS Lumina In Vivo Imaging System (Caliper Life Sciences, Hopkinton, MA). For imaging, the mice were intraperitoneally injected with 150 mg/kg BW of D-luciferin (PerkinElmer, Waltham, MA), and 5 minutes later, the photon flux levels were detected and analyzed using Living Image Software (version 3.0; XENOGEN). At 12 weeks of age, the mice were anesthetized for measurement of BW and blood sampling and then euthanized. The tumor volumes were calculated using a modified ellipsoid formula: volume = (length 3 width 2 3 0.52). Paraffin-embedded formalin-fixed tumors were cut into 5-mm sections and prepared for immunofluorescent staining as described previously (12) . Additional information on the antibodies used in this study is given in Table 1 .
Immunohistochemistry

Small interfering RNA knockdown of AR expression and cell proliferation assay
To knockdown AR, we used order-designed small interfering RNA (siRNA; Theoria Science, Tokyo, Japan), which was designed to target human AR. As a control, we used negative control siRNA from the same company. For transfection, LNCaP cells were plated at 3 3 10 5 cells per well in six-well plates and transfected with 10 nmol/L of siRNA targeting AR or with negative control siRNA using MISSION ® siRNA Transfection Reagent (Sigma-Aldrich). Seventy-two hours after transfection, cells were subjected to the cell proliferation assay, BrdU assay, and western blot analysis. The siRNA knockdown efficiency was confirmed by western blotting and immunohistochemical analysis of AR.
Plasmids, transient transfections, and luciferase assay
To evaluate AR activation, luciferase reporter assays were performed with LNCaP and 22Rv1 cells transiently transfected with pGL3-MMTV or PSA-LUC reporter constructs, as described previously (13) . Brieflyplease check renumbering for accuracy., LNCaP and 22Rv1 cells were transfected with 0.5 mg of reporter DNA using FuGENE HD Transfection Reagent (Roche). Next, cells were maintained in media containing 10% DCCS-FBS with 10 mM of S42 or DMSO plus 10 nM of DHT or EtOH for 24 hours. Luciferase activity was examined using the Dual-Luciferase Reporter Assay (Promega). Transfection efficiency was normalized to Renilla luciferase activity generated by cotransfection of cells with 10 ng per well of pRL-SV40 (Promega).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed using an EZ-Magna ChIP HiSens Assay Kit (Millipore) according to the manufacturer's instructions. Briefly, LNCaP cells (1 3 10 7 cells/100-mm disc) treated with 10 mM of S42 or DMSO plus 10 nM of DHT or EtOH in medium containing 10% DCCS-FBS for 24 hours were cross-linked by adding 1% formaldehyde directly to the culture medium for 10 minutes at room temperature. Cells were harvested, and soluble chromatin was prepared. Chromatin was immunoprecipitated using 1 mg of either antihuman AR (catalog no. 
Statistical analysis
All results are expressed as mean 6 standard error of the mean. Statistical analyses were performed using the unpaired t test, one-way analysis of variance, or two-way analysis of variance followed by Bonferroni post hoc test as appropriate. P values ,0.05 were considered statistically significant. 
Results
S42 inhibited PC cell proliferation
We first examined the in vitro effect of S42 on the growth of four cultured human PC cell lines, LNCaP, 22Rv1, PC-3, and DU145. Treatment with 10 mM of S42 alone significantly decreased the proliferation of PC cells compared with vehicle (EtOH-DMSO) at 48, 72, and 96 hours for LNCaP (P , 0.05, P , 0.0001, and P , 0.05, respectively); at 24, 48, 72, and 96 hours for 22Rv1 (P , 0.05, P , 0.001, P , 0.0001, and P , 0.0001, respectively); and at 72 hours for PC-3 (P , 0.0001) (Fig. 1A-1C) . DHT had the opposite effect and significantly stimulated the proliferation of LNCaP cells (P , 0.05 at 96 hours) and 22Rv1 cells (P , 0.05 at 48 hours, P , 0.01 at 96 hours) compared with vehicle treatment (Fig. 1A and 1B ). The addition of S42 suppressed the DHT-induced proliferation of LNCaP cells (P , 0.01, P , 0.0001, and P , 0.001 at 48, 72, and 96 hours, respectively), 22Rv1 cells (P , 0.0001 at 24 to 96 hours, the entire time point), and PC-3 cells (P , 0.01, P , 0.0001, and P , 0.05 at 24, 72 and 96 hours, respectively) (Fig. 1A-1C ). S42 appeared to have a more marked effect on DHT-stimulated proliferation than on basal proliferation. The effects of S42 on basal and DHTstimulated cell proliferation were strong in both LNCaP and 22Rv1 cells, followed by PC-3 cells (Fig. 1A-1C) . However, we observed no significant effects of DHT or S42 on the proliferation of DU145 cells (Fig. 1D ).
S42 attenuated DNA replication in PC cells but did not induce apoptosis
To examine whether S42 inhibits cell proliferation by blocking DNA synthesis and/or by inducing apoptosis, we performed BrdU and TUNEL assays, respectively. At 48 hours after treatment, S42 not only inhibited basal BrdU incorporation in LNCaP, 22Rv1, and PC-3 cells (P , 0.05, P , 0.01, and P , 0.05 vs DMSO controls, respectively) ( Fig. 2A-2C ), but it also significantly inhibited DHT-induced BrdU incorporation in these three cell lines (P , 0.05 for LNCaP cells, P , 0.0001 for 22Rv1 cells, and P , 0.05 for PC-3 cells vs DHT alone) ( Fig. 2A-2C ). In contrast, BrdU incorporation in DU145 cells was unaffected by DHT or S42 (Fig. 2D) .
Next, we examined apoptosis after 48-hour treatment with S42 in the presence or absence of DHT. However, TUNEL-positive cells (i.e., apoptotic cells) were not detected in any of the treated cell lines, including LNCaP (Supplemental Fig. 1 ). These results indicate that although S42 treatment of 24 hours significantly decreased DNA synthesis in PC cells, it did not induce apoptosis.
Because S42 had a significant effect on the proliferation of the androgen-sensitive PC cell lines LNCaP and 22Rv1, we next examined the basal levels of AR protein in these cells by western blot analysis. We found that AR was abundant in LNCaP and 22Rv1 cells. The 22Rv1 cells expressed not only the full-length AR (AR-FL) of 110 kDa but also the truncated isoform of 77 to 78 kDa (i.e., AR-V7), as previously reported (14, 15) . In contrast, AR was barely detectable in PC-3 and DU145 cells (Fig. 3A) . We therefore focused our analysis in the following experiments mainly on LNCaP cells to determine the mechanism of S42 action.
Expression of AR, IGF-1R, and IR proteins in LNCaP and 22Rv1 cells was stimulated by DHT but suppressed by S42
The effect of DHT and/or S42 on the expression of AR, IGF-1R, and IR in cultured LNCaP and 22Rv1 cells was examined by western blot analysis. The basal expression of AR in LNCaP was downregulated by S42 treatment (P , 0.05 vs DMSO) (Fig. 3B) , whereas it was not affected by S42 in 22RV1 cells (Fig. 3C) . The DHT-induced upregulation of AR [full-length AR (AR-FL)] in LNCaP and 22Rv1 cells (P , 0.05 vs EtOH-DMSO for both) was significantly suppressed by cotreatment with S42 (P , 0.01 vs DHT-DMSO for both) (Fig. 3B and 3C ). AR-V7 was not affected by S42 at the basal and DHT-stimulated conditions (statistical data not shown). Similarly, the basal expression of IGF-1R in LNCaP cells was downregulated by S42 (P , 0.05 vs EtOH-DMSO) and upregulated by DHT, although this effect was not statistically significant (P = 0.0822 vs EtOH-DMSO), and the effect of DHT was significantly suppressed by S42 (P , 0.01 vs DHT-DMSO) (Fig. 4A) . IGF-1R protein levels in 22Rv1 cells were barely detectable (data not shown). In both LNCaP and 22Rv1 cells, the basal expression of IR was not affected by S42. Although DHT did not induce upregulation of IR, S42 significantly suppressed the expression level of IR in LNCaP and 22Rv1 cells (P , 0.05 vs DHT-DMSO for both) (Fig. 4B  and 4C ).
The Akt (PKB) pathway is a central downstream effector of IR/IGF-1R signaling in PC cells, including LNCaP cells (16) . However, we did not observe significant changes in the expression levels of Akt and phosphorylated Akt in LNCaP and 22Rv1 cells upon treatment with DHT and/or S42 (Supplemental Fig. 2A-2D) . Although 22Rv1 cells have a wild-type phosphatase and tensin homolog (PTEN) (17) , LNCaP cells exhibit constitutive activation of Akt signaling by PTEN inactivation (16) . S42 probably does not affect Akt signaling regardless of the presence or absence of PTEN expression.
S42 suppressed PC cell proliferation through inhibition of ERK-MAPK
Because ERK-MAPK is a component of one of the main signaling pathways for proliferation in PC cells (18) , we performed western blotting to examine whether S42 attenuates ERK-MAPK activation in LNCaP and 22Rv1 cells. We found that S42 tended to suppress the expression of phosphorylated (activated) ERK-MAPK, although this effect was not statistically significant in LNCaP cells (P = 0.0985) (Fig. 4D ) and in 22RV1 cells (Fig. 4E) . Although DHT did not activate ERK-MAPK, the addition of S42 to DHT-treated cells significantly suppressed the phosphor-ERK-MAPK levels in LNCaP and 22Rv1 cells (P , 0.01 vs DHT for both) (Fig. 4D and 4E ). These data indicate that S42 suppresses LNCaP and 22Rv1 cell proliferation through ERK-MAPK inhibition, at least in part, but does not induce apoptosis. . PC cells were grown to 60% to 70% confluence and then incubated with the indicated combinations of DMSO, EtOH, 10 of mM S42, and 10 nM of DHT for 24 to 48 hours. The BrdU incorporation assay was performed as described in the Methods section. Data are mean 6 standard error of the mean of n = 5 replicates and are expressed as the ratio of BrdU incorporation in treated vs untreated (EtOH-DMSO) cells. Two-way analysis of variance was performed to calculate statistical significance. *P , 0.05 and **P , 0.01 vs EtOH-DMSO; 
S42 attenuated PC cell proliferation through ARs
Because the highest AR (AR-FL) expression was observed in LNCaP cells, we used this cell line in the subsequent experiments. The antiproliferative effect of S42 was completely reversed by AR knockdown using siRNA. To confirm the substantial reduction in ARs by the AR-targeted siRNA, we conducted western blotting and immunohistochemistry (Fig. 5A and 5B). AR knockdown abolished the S42-induced reduction in LNCaP cell number and BrdU incorporation in LNCaP cells (Fig. 5C and 5D ), suggesting that S42 decreased the LNCaP cell number through AR activation. Similarly, AR knockdown abolished the reduction in both basal and DHT-induced expression of IGF-1R and phosphor-ERK-MAPK (Fig. 5E-5G ). These data strongly suggest that AR is functionally essential in LNCaP cells.
S42 inhibited the transcription of the AR gene and accelerated the proteasomal degradation of DHT-induced expression of AR
Furthermore, in a luciferase assay using the androgen response element in the PSA promoter, S42 inhibited the 24-hour DHT-induced PSA transactivation in LNCaP (Fig. 6A ) and 22Rv1 cells (data not shown).
To elucidate the possible regulation of AR by S42 at the protein level, we next studied the effect of S42 on AR protein degradation after new protein synthesis was blocked by CHX. As expected, pretreatment of the cells with CHX caused a decrease in protein stability. S42 did not essentially affect protein stability. On the other hand, DHT significantly increased the protein stability of the cells pretreated with CHX. However, S42 significantly decreased the protein stability induced by DHT (Fig. 6B  and 6C ). To further elucidate whether S42 induces AR protein degradation via the ubiquitin-proteasome system, we added the 26S proteasome inhibitor MG-132 to the cells with or without DHT/S42. The reduction in AR expression by S42 was barely affected by combined treatment with MG-132 (Fig. 6D) . These data suggest that S42 affects not only DHT-dependent AR transcriptional activity but also protein stability.
S42 affected the interaction of AR with the promoter region of the PSA gene
To determine whether S42 intervenes with the chromatin binding of AR, ChIP analysis was performed on LNCaP cells treated with DHT and/or S42 for 24 hours. Target sequence primers were designed to amplify regions within the PSA promoter (ARE I, ARE II) and enhancer (ARE III) (Fig. 7A) . As shown in Fig. 7B , real-time qPCR analysis revealed that S42 significantly inhibited both basal and DHT-induced AR binding to the ARE sites located in the PSA promoter and enhancer.
S42 attenuated LNCaP growth in vivo
We examined the ability of S42 to suppress PC cell growth in vivo. We subcutaneously injected CAG-Luc LNCaP cells (stably expressing a luciferase reporter construct) into 6-week-old male athymic mice and monitored tumor growth by in vivo imaging once a week. The mice were not castrated to allow the xenografted LNCaP cells to be stimulated by endogenous androgens, including DHT. Two weeks after LNCaP cells were xenografted, mice were injected with S42 (0.1 or 1.0 mg/ kg BW) twice weekly for an additional 4 weeks. At 12 weeks of age, BWs of the control (vehicle) group (n = 6), 0.1-mg/kg S42 group (n = 6), and 1-mg/kg group (n = 7) were 24.06 6 0.72 g, 24.48 6 1.11 g, and 25.42 6 0.46 g, respectively, and they were statistically not different from each other. Plasma glucose and serum total testosterone levels of the respective groups were statistically not different from each other.
Tumor formations were visualized by in vivo imaging of the fluorescence intensity derived from the CAG-Luc LNCaP tumor cells just before euthanasia (Fig. 8A) . This evaluation showed a trend of dose-dependent suppression of tumor growth by S42 compared with vehicle (P = 0.439 and P = 0.062 for 0.1 and 1 mg/kg S42, respectively), and the tumor fluorescence intensity of the 1-mg/kg S42 group was significantly lower than that of the 0.1-mg/kg S42 group (P , 0.05) (Fig. 8B) . Actual tumors and quantification of the effect of S42 on their growth are shown in Fig. 8C and 8D . Tumor weights were decreased dose-dependently by S42, with a significantly greater effect observed with 1-mg/kg S42 than with 0.1-mg/kg S42 (P = 0.181 and P , 0.05 for 0.1-and 1-mg/kg S42, respectively, vs vehicle) (Fig. 8D) . PSA mRNA levels in the tumors were analyzed by qPCR and found to be dose-dependently decreased by S42 treatment (Fig. 8E ) (P = 0.057 and P , 0.05 for 0.1-and 1-mg/kg S42, respectively). There was also a statistically significant difference between PSA mRNA levels in tumors from the 0.1-and 1-mg/kg S42 groups (P , 0.01) (Fig. 8E) .
Finally, we performed immunohistochemical analysis of various markers using paraffin-embedded sections of PC tumors excised at euthanasia. Quantification of expression was calculated as the mean number of positiveimmunostaining cells divided by the total number of nuclei stained with 4 0 ,6-diamidino-2-phenylindole. The expression of Ki67, a marker of cell proliferation (Fig. 9A  and 9B ) and that of P504S, a PC marker (Supplemental Fig. 3A and 3B) , were suppressed by S42 treatment in a dose-dependent manner compared with control mice, with statistical significance ( Fig. 9A and 9B ; Supplemental Fig. 3A and 3B) . Similarly, consistent with our in vitro data, we found statistically significant and dosedependent reductions in the expression of AR (Fig. 9C  and 9D ), IGF-IR (Supplemental Fig. 3C and 3D ), IR (Supplemental Fig. 3E and 3F) , and phospho-ERK-MAPK ( Fig. 9E and 9F ) by S42 treatment compared with control mice. These data suggest that S42 attenuated PC growth in vivo by the same mechanism observed in vitro, namely through inhibition of the expression of AR, IGF-1R, IR, and ERK-MAPK.
Discussion
The androgen-AR system plays vital roles in a wide array of pathophysiological processes, including PC growth. In the current study, S42 suppressed basal and DHTinduced PC cell growth in vitro. Furthermore, BrdU and TUNEL assays revealed that this suppressive effect was mediated mainly by inhibition of cell proliferation and not by promotion of apoptosis.
It has been reported that proliferation of LNCaP and 22Rv1 cells is androgen-dependent, whereas PC-3 and DU145 proliferate in an androgen-independent manner. Consistent with this, we did not observe DHT-dependent cell growth of PC-3 or DU145 cells. S42 showed a remarkable antiproliferative effect on LNCaP and 22RV1 cells, both of which expressed relatively high levels of AR Real-time qPCR analysis was performed with primers that cover the ARE sites in the human PSA promoter and enhancer; the negative locus was a GAPDH promoter primer set.
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Ct calculations reporting fold enrichment at the positive locus over the negative locus are reported. Data are the mean 6 standard error of the mean of triplicate samples. Two-way analysis of variance was performed to calculate statistical significance. *P , 0.05 and **P , 0.01 vs EtOH-DMSO; # P , 0.05 and ## P , 0.01 vs DHT-DMSO. ARE, androgen response element; ATG, translation start codon. among the four PC cell lines. In addition, the suppressive effect of S42 on the androgen-dependent cell lines LNCaP and 22Rv1 was more remarkable in DHT-dependent cell proliferation than in basal cell growth. These findings are compatible with our previous data showing that S42 antagonized DHT-dependent AR transactivation in vitro (9) . In cultured LNCaP cells, DHT increased AR protein expression by stabilizing AR mRNA (19) . In our study, DHT increased AR protein levels in cultured LNCaP cells, which were significantly suppressed by S42. Moreover, S42 decreased the basal level of AR protein and the DHT-induced increase in AR protein expression. A similar effect of DHT and/or S42 was observed in 22Rv1 cells, which are derived from the xenograft line CWR22R and express PSA mRNA, and the full-length and truncated forms of AR protein (14, 15) . Furthermore, S42 inhibited DHT-induced PSA transactivation and AR binding to the ARE sites located in the PSA promoter in LNCaP cells. These data suggest that the effect of S42, at least in androgen-sensitive cell lines, may be mediated mainly by AR. This concept was strongly supported by the fact that the suppressive effects of S42 on LNCaP cell proliferation and DNA synthesis were almost completely abolished by the siRNA-mediated knockdown of AR. The suppression of the S42 effect on LNCaP cells was also observed in the expression of IGF-1R and phospho-ERK-MAPK, and these effects were also abolished by the siRNA-mediated knockdown of AR. These results suggest that the DHT-AR system is the upstream target of S42.
Androgen-deprivation therapy (ADT), usually by combination of androgen blockade with a luteinizing hormone-releasing hormone agonist and an antiandrogen, is the standard of care for patients with PC. However, nearly all patients progress to treatmentresistant PC, also known as castration-resistant PC. Among the various suggested mechanisms by which AR may be reactivated in a low-androgen environment (20) , signaling by growth factors, especially IGF-1, is reportedly of particular importance for PC proliferation (21) (22) (23) (24) (25) (26) . IGF-1 binding to its receptor, IGF-1R, activates a number of intracellular signaling pathways, especially the phosphoinositide 3-kinase (PI3K)/Akt pathway (16) . Specifically, increases in IGF-1 and/or IGF-1R expression (23, 27, 28) and loss of the tumor suppressor gene PTEN (29, 30) elicit increased activity of the PI3K/Akt pathway and greatly contribute to PC progression.
Recent studies have also revealed that high serum insulin levels, mostly observed in obese individuals, were associated with increased incidence of PC (31) (32) (33) . We previously demonstrated that the transcription factor Foxo1 is a corepressor of AR transactivation and is functionally inactivated by IGF-1/insulin-PI3K-Akt signaling via Akt-mediated phosphorylation (13) . This is thought to be one mechanism by which AR is activated by IGF-1/insulin signaling. In our present study, we found that DHT not only upregulated IGF-IR expression in LNCaP cells, as we (13) and others (34) have previously reported, but also increased the expression of IR and Akt, which would sensitize PC cells to the effects of IGF-1/ insulin. However, we did not observe a significant change in the expression of Akt and phospho-Akt, downstream molecules of IGF-1/insulin, by DHT and/or S42 in cultured LNCaP cells. LNCaP cells have a frameshift mutation in PTEN, a tumor suppressor gene identified in human chromosome 10q23 (35) . Thus, in these cells, Akt (PKB) is constitutively activated because of the inactivation of PTEN, an inhibitor of PI3-kinase (16) . Although 22Rv1 cells have the wild-type PTEN gene (17) , in our study, DHT and/or S42 did not have any effect on the expression of Akt and phospho-Akt as observed in LNCaP cells. These results suggest that S42 does not affect Akt signaling regardless of the presence or absence of PTEN expression. Interestingly, S42 significantly attenuated the DHT-induced expression of the gates of the signaling, AR, IGF-1R, and IR.
As to the mechanism of the effect of S42 on AR, it was suggested that S42 suppressed DHT-induced transcriptional upregulation and the protein stability of AR. These events may lead to a decrease in total signaling for the proliferation of androgen-sensitive PC cells, thus contributing to the antiproliferative effect of S42 on LNCaP and 22Rv1 cells.
The ERK-MAPK pathway, mainly triggered by mitogens and cytokines such as interleukin (IL)-6, is a major stimulator of proliferation in PC cells (18) . We found that proliferation of LNCaP cells, which produce IL-6, was at least partly dependent on ERK-MAPK activation (36) . Recently, a phase 1 clinical trial revealed the ability of an anti-IL-6 antibody (siltuximab) to inhibit ERK1/2 phosphorylation in prostate tumors (37) . Therefore, we examined whether S42 attenuates ERK-MAPK activation in PC cells. Although a clear induction of phospho-ERK1/2 by DHT was not observed, we did find that S42 significantly reduced the effects of DHT on ERK1/2 phosphorylation in LNCaP and 22Rv1 cells. PC-3, a line of hormone-refractory PC cells, also expresses IL-6, which is partially regulated by the ERK-MAPK pathway (38, 39) .
Interestingly, we found that S42 significantly reduced the effects of DHT on ERK1/2 phosphorylation in PC-3 cells (Supplemental Fig. 4) , despite the fact that S42 did not affect the expression levels of AR, IGF-1R, and IR (data not shown). Although androgens activate the Src/Raf-1/ERK pathway through IGF-1R upregulation (13), our observation that S42 suppressed the castrationresistant cell line PC-3 suggests that S42 may also exert its antiproliferative effect through an androgen-independent mechanism, such as ligand-independent AR activation. Recent loss-of-function studies have revealed that even in castration-resistant PC cells, AR still plays a key role in hormone-refractory progression of PC cells (40, 41) . It has been speculated that this involves an adaptation of AR signaling to function under low or no androgen levels (42) . This mechanism may be partially, if not completely, castration resistant. However, our results suggest that attenuation of ERK-MAPK activation may be an important mechanism for the antiproliferative effect of S42 on PC cells.
ADT frequently causes obesity and the metabolic syndrome (43) . Indeed, men have developed insulin resistance as early as 3 months after starting ADT (44) . One explanation for this is the importance of the androgen-AR system in maintaining body composition, particularly the balance between fat accumulation and skeletal muscle mass, partly through the promotion of energy expenditure (6). Obesity and/or insulin resistance also cause cancer, including PC, via DNA damage induced by increased oxidative stress and activation of insulin/ IGF-1 signaling, among other effects (31, (45) (46) (47) . Thus, a vicious cycle between ADT and PC progression seems to be present. In this respect, the development of SARMs possessing beneficial activities against obesity/metabolic syndrome and PC progression is a promising alternative treatment of PC in the future. We previously reported a beneficial effect of S42 in lowering serum triglyceride levels in orchiectomized rats through modification of lipogenic and lipolytic pathways in the liver and visceral fat (9) . In addition, we recently observed the antiobesity activity of S42 in a mouse model of high-fat diet-induced obesity (unpublished results). Thus, S42 may be a good candidate SARM for targeting PC without causing obesity or metabolic syndrome.
Because most SARMs have been developed with the goal of producing beneficial effects on bone and muscle mass without affecting the prostate (7, 8, 48) , there has been little investigation of their potential for PC treatment. A steroidal SARM, MK-4541, was recently shown to have an anti-PC effect in vitro and in vivo in a PC xenograft model (49, 50) . In our study, S42 also suppressed the growth of LNCaP xenografts in mice, which was accompanied by suppression of serum PSA levels. Consistent with our in vitro data, levels of phosphor-ERK-MAPK, IGF-IR, and IR in LNCaP tumors in mice were decreased by treatment with S42, further endorsing the proposed mechanism.
In summary, we demonstrated that S42 attenuated growth of the androgen-dependent PC cell lines LNCaP and 22Rv1 in vitro and of LNCaP cells even in vivo by inhibiting the expression of AR and IGF-1R and by suppressing ERK-MAPK activation. The attenuation of ERK-MAPK activation was observed even in the castration-resistant cell line PC-3, suggesting androgendependent and independent mechanisms are involved in the effect of S42 on PC cells.
